Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: A systematic review

• Published in: Surgical oncology 2017-09, Vol.26 (3), p.268-275
• Main Authors: Akinwande, Olaguoke, MD, Dendy, Meaghan, Ludwig, Johannes M., MD, Kim, Hyun S., MD
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents, Phytogenic - administration & dosage; Camptothecin - administration & dosage; Camptothecin - analogs & derivatives; Cancer therapies; Chemoembolization, Therapeutic - methods; Chemotherapy; Clinical trials; Colorectal cancer; Colorectal Neoplasms; Criteria; Documents; Drug delivery; Effectiveness; Epidemiologic Methods; Hematology, Oncology and Palliative Medicine; Humans; Injections, Intra-Arterial; Irinotecan; Liver; Liver Neoplasms - secondary; Liver Neoplasms - therapy; Metastases; Metastasis; Microspheres; Patients; Quality; Safety; Solid tumors; Studies; Surgery; Survival; Toxicity; Tumors
• ISSN: 0960-7404; 1879-3320
• DOI: 10.1016/j.suronc.2017.05.003

Abstract Purpose To systematically review the safety and efficacy of transarterial drug-eluting beads, irinotecan (DEBIRI) for the treatment of pretreated patients with unresectable colorectal liver metastases (CRLM). Methods A systematic search of the current literature was conducted to extract publications reporting on the use of DEBIRI for CRLM. Data on the safety and efficacy was extracted and tabulated. Weighted average values (WAV) were calculated for each variable to provide a single value representing the pooled safety and efficacy data. Results 13 studies (15 treatment arms) were evaluated, comprising a total of 850 patients. There were 6 prospective phase I/II trials, 5 retrospective trials and 2 randomized control trials. All papers involved patients previously treated with systemic chemotherapy. The weighted average all-grade toxicity rate was 35.2% (range; 6–100%). The high-grade WAV toxicity rate was 10.1% (range; 0–32%). Weighted average response rates were 56.2% and 51.1% according to RECIST (Response Evaluation Criteria in Solid Tumors) and modified RECIST/EASL (European Association for the Study of the Liver) response criteria respectively. The weighted average progression-free survival and overall survival were 8.1 months and 16.8 months, respectively. Conclusion Transarterial DEBIRI is safe and effective in the treatment of unresectable CRLM to the liver. Further studies are warranted to better define its role in the treatment algorithm of this patient subset.